In a single-center, 5-year prospective study of over 500 patients with type 2 diabetes, those with baseline plasma C16 levels 0.8 mol/L had a 2.8-fold higher risk of progressing to end-stage renal disease (ESRD) (HR = 2.83, 95% CI:1.624.94), independent of conventional factors such as glycemic control, blood pressure status, and UACR [145]
Consumer protection matters
Table of Contents How GLP-1 Medications Affect Taste and Food Preferences Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), are increasingly prescribed for type 2 diabetes management and weight loss
In addition, in January 2025, Medicare announced it will include semaglutide products (Ozempic, Rybelsus, and Wegovy) in its second round of drug price negotiations, treating all three brands as a single drug due to their shared active ingredient.28 With negotiated prices set to take effect in 2027, this could significantly reduce costs for Medicare beneficiaries